
1. General Information
BIOMAb EGFR Injection contains Nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). It is a targeted anticancer therapy used for certain EGFR-expressing cancers, particularly head and neck cancers, with its exact approved indications varying by country.
BIOMAb EGFR is administered as an intravenous infusion by a healthcare professional. It is not intended for self-administration.
2. Product Information
- Brand: BIOMAb EGFR
- Active ingredient: Nimotuzumab
- Strength: 50 mg/10 mL vial
- Dosage form: Solution for intravenous infusion
- Therapeutic class: Targeted anticancer monoclonal antibody
- Target: Epidermal Growth Factor Receptor (EGFR)
- Manufacturer: Biocon/Biocon Biologics, India
- Storage: Generally refrigerated at 2°C–8°C; follow the product label and prescribing information.
- Packaging: Commonly supplied as a 10 mL vial containing 50 mg Nimotuzumab.
3. Uses of BIOMAb EGFR
Nimotuzumab is used as part of cancer treatment for certain EGFR-expressing malignancies. Its established use includes:
- Head and neck cancers, particularly squamous cell carcinoma
- Certain gliomas/brain tumors in jurisdictions where approved
- Nasopharyngeal cancer in certain countries and clinical settings
The indication and treatment combination can differ according to the patient's cancer type, stage, EGFR status, and the regulatory approval applicable in the country.
4. Benefits of BIOMAb EGFR
The principal benefit of Nimotuzumab is its targeted mechanism of action. It binds to EGFR and interferes with EGFR-mediated signaling involved in cancer-cell growth and proliferation. It may be used alongside radiotherapy and/or chemotherapy when appropriate for the patient's cancer.
Potential therapeutic benefits include:
- Targeted action against EGFR-related cancer signaling
- Use as part of combination cancer treatment
- May help inhibit tumor-cell growth
- Provides an additional targeted-treatment option for eligible patients
Important: Benefits vary between patients and depend on cancer type, stage, treatment regimen, and response to therapy. It should not be described as a guaranteed cure for cancer.
5. Side Effects
Like other monoclonal antibody therapies, BIOMAb EGFR can cause adverse effects. Reported effects include:
- Fever
- Chills
- Headache
- Nausea
- Skin rash or itching
- Mucositis
- Fatigue
- Changes in blood pressure
- Infusion-related reactions
Serious or persistent symptoms should be reported promptly to the treating healthcare professional.
6. Common Side Effects
Some commonly reported side effects include:
- Fever
- Chills
- Headache
- Nausea
- Fatigue
- Itching or skin rash
- Mucositis
The occurrence and severity of side effects can vary from patient to patient.
7. How to Use BIOMAb EGFR
BIOMAb EGFR must be administered intravenously by a doctor, nurse, or other appropriately trained healthcare professional.
The dose and treatment schedule are determined by the oncologist according to the patient's diagnosis, treatment plan, body condition, and applicable clinical guidance. Do not self-inject or change the prescribed dose or treatment schedule.
The vial should be stored and handled according to the manufacturer's instructions, including appropriate refrigerated storage where specified.
8. How BIOMAb EGFR Works
Nimotuzumab is a humanized monoclonal antibody that specifically targets EGFR, a receptor involved in signaling pathways that regulate cell growth and proliferation.
By binding to EGFR, Nimotuzumab interferes with EGFR signaling and can inhibit processes that support the growth and survival of certain cancer cells. This makes it a form of targeted cancer therapy.
9. Safety Advice
- Use BIOMAb EGFR only under the supervision of an oncologist.
- Inform your doctor about all medicines and treatments you are receiving.
- Tell your healthcare provider if you have previously experienced an allergic or infusion reaction to monoclonal antibodies.
- Seek immediate medical attention for severe allergic symptoms, breathing difficulty, swelling, severe dizziness, or other serious reactions during or after infusion.
- Discuss pregnancy or plans to become pregnant with your doctor before treatment.
- Breastfeeding should be discussed with the treating physician.
- Keep the medicine refrigerated according to the product label and protect it from inappropriate storage conditions.
- Do not use the product if the vial or packaging appears damaged or if the medicine does not meet the product's specified appearance/storage requirements.
- Because BIOMAb EGFR is a prescription anticancer medicine, treatment decisions should be made by a qualified healthcare professional.
10. Frequently Asked Questions (FAQs)
Q1. What is BIOMAb EGFR Injection?
BIOMAb EGFR is a targeted anticancer medicine containing Nimotuzumab, a humanized monoclonal antibody that targets EGFR.
Q2. What is the strength of BIOMAb EGFR?
A commonly available presentation contains 50 mg Nimotuzumab in 10 mL.
Q3. What is BIOMAb EGFR used for?
It is used for certain EGFR-expressing cancers, particularly head and neck cancers, with additional indications depending on local regulatory approvals.
Q4. Can BIOMAb EGFR cure cancer?
It should not be considered a guaranteed cure. It is a targeted anticancer treatment that may form part of a broader cancer-treatment plan.
Q5. How is BIOMAb EGFR administered?
It is administered by intravenous infusion under medical supervision.
Q6. Can I administer BIOMAb EGFR myself?
No. It should be administered by an appropriately trained healthcare professional.
Q7. How should BIOMAb EGFR be stored?
The commonly listed product presentation is stored under refrigeration at 2°C–8°C. Always follow the manufacturer's current storage instructions.
Q8. What are the common side effects?
Fever, chills, headache, nausea, fatigue, itching/rash and mucositis have been reported.
Q9. Is BIOMAb EGFR available for export?
International supply depends on the destination country's pharmaceutical regulations, prescription requirements, import rules, product registration and applicable export documentation.
Q10. Who should determine the dose?
The treating oncologist should determine the dose and treatment schedule based on the patient's condition and applicable treatment protocol.
11. Substitutes / Alternatives
There is no universal direct substitute for BIOMAb EGFR. Alternative anticancer treatments depend on the cancer type, stage, molecular characteristics, previous treatment and the patient's overall condition.
Depending on the indication, an oncologist may consider other EGFR-targeted therapies or other cancer-treatment approaches. Examples can include cetuximab or other targeted/systemic therapies where clinically and regulatorily appropriate.
These medicines are not automatically interchangeable with Nimotuzumab. A qualified oncologist must determine whether an alternative is appropriate.
12. SEO Keywords
- BIOMAb EGFR Injection exporter from India
- BIOMAb EGFR 50 mg Injection exporter
- Nimotuzumab 50 mg Injection exporter India
- BIOMAb EGFR Nimotuzumab supplier India
- BIOMAb EGFR Injection pharmaceutical exporter
- Nimotuzumab Injection wholesale supplier India
- BIOMAb EGFR 50 mg/10 mL supplier
- Nimotuzumab anticancer injection supplier
- BIOMAb EGFR medicine exporter from Nagpur
- BIOMAb EGFR cancer medicine supplier India
- Nimotuzumab oncology medicine exporter
- BIOMAb EGFR Injection international supplier
- BIOMAb EGFR Injection for head and neck cancer
- Nimotuzumab targeted cancer therapy supplier
- BIOMAb EGFR pharmaceutical products India
- BIOMAb EGFR Injection supplier to USA
- BIOMAb EGFR Injection supplier to UK
- BIOMAb EGFR Injection supplier to Australia
- BIOMAb EGFR Injection supplier to Singapore
- BIOMAb EGFR Injection supplier to Canada
- BIOMAb EGFR Injection supplier to South Korea
- BIOMAb EGFR Injection supplier to UAE
- Nimotuzumab 50 mg pharmaceutical exporter India
- Targeted anticancer medicine exporter from India
- Oncology medicine exporter from Nagpur India
Keywords







